Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesSales of Property, Plant and EquipmentShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

aTYR PHARMA (ATYR) Share-based Compensation (2019 - 2025)

aTYR PHARMA (ATYR) has disclosed Share-based Compensation for 7 consecutive years, with $1.2 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Share-based Compensation rose 56.75% year-over-year to $1.2 million, compared with a TTM value of $5.0 million through Dec 2025, up 67.18%, and an annual FY2025 reading of $5.0 million, up 67.18% over the prior year.
  • Share-based Compensation was $1.2 million for Q4 2025 at aTYR PHARMA, down from $1.3 million in the prior quarter.
  • Across five years, Share-based Compensation topped out at $1.3 million in Q3 2025 and bottomed at $360000.0 in Q1 2021.
  • Average Share-based Compensation over 5 years is $717700.0, with a median of $658500.0 recorded in 2023.
  • The sharpest move saw Share-based Compensation decreased 14.89% in 2021, then soared 79.5% in 2025.
  • Year by year, Share-based Compensation stood at $414000.0 in 2021, then skyrocketed by 46.14% to $605000.0 in 2022, then rose by 8.93% to $659000.0 in 2023, then rose by 16.84% to $770000.0 in 2024, then soared by 56.75% to $1.2 million in 2025.
  • Business Quant data shows Share-based Compensation for ATYR at $1.2 million in Q4 2025, $1.3 million in Q3 2025, and $1.3 million in Q2 2025.